Navigation Links
Silencing hepatitis B virus prevent recurrence of liver cancer
Date:6/24/2010

(PHILADELPHIA) Previous studies have shown that antiviral treatment reduces the incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). But now, researchers from the Division of Gastroenterology and Hepatology at Thomas Jefferson University are reporting that the antiviral therapy also prevents recurrence of HCC and extends patients' lives.

The standard of care for patients with HCC is local ablation of the tumor, unless it is large or has metastasized. However, HCC tumors often recur, or new lesions develop. In the International Journal of Cancer, Hie-Won Hann, M.D., professor of Medicine at Jefferson Medical College of Thomas Jefferson University, and colleagues reported that the median survival in patients who received antiviral therapy after HCC diagnosis was 60 months in patients. In those who did not receive antiviral therapy, the median survival was 12.5 months.

"Before the antiviral drugs were developed, patients would often develop new lesions within a few months of tumor ablation because we were not treating the underlying virus that is causing the liver cancer," Dr. Hann said. "The virus drives the cancer, and by suppressing the virus and making it undetectable we can extend the survival for these patients."

The small study included 15 CHB patients who received local ablation of a single HCC tumor that was less than four cm. The first six patients were diagnosed between 1991 and 1997, prior to the development of antiviral therapy. These patients were considered historical controls.

The other nine patients were diagnosed between 2000 and 2004. These patients began ongoing antiviral therapy with lamivudine immediately after HCC diagnosis. Other antiviral medications, such as tenofovir and adefovir were added to the regimen if resistance to lamivudine developed, or even without drug resistance.

All patients who received the antiviral therapy maintained undetectable hepatitis B virus in serum and continued the therapy. Seven of the nine patients have not developed a new HCC or recurrence. The longest survivors are the two patients who came with HCC in 2000. They are doing well, free of caner for more than 10 years. All patients continue with the antiviral therapy and are followed at three to four month intervals.

"The other option for these patients is liver transplantation, which carries its own risks," said Robert Coben, M.D., associate professor of Medicine at Jefferson Medical College of Thomas Jefferson University, who was involved in the study. "This is an attractive alternative for this patient population."


'/>"/>

Contact: Emily Shafer
emily.shafer@jefferson.edu
215-955-6300
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. NVHR: Administrations 2011 Budget Proposal Shortchanges Five Million Americans Afflicted with Chronic Viral Hepatitis
2. NVHR Issues Challenge to Administration, Congress: Dont Leave 5 Million Americans Afflicted with Chronic Viral Hepatitis Out in the Cold with Budget Freeze
3. New Treatment Eyed for Hepatitis C
4. Treatment for chronic hepatitis C: A phase II study
5. New Hepatitis C Treatment Shows Promise
6. NVHR Offers Congressman Hank Johnson Support & Encouragement as He Battles Chronic Hepatitis C Virus
7. Hepatitis B Foundation awards UT School of Public Health professor
8. Key to Hepatitis C May Be Two Cellular Proteins
9. IOM report recommends steps to tackle hepatitis B and C
10. New screening system for hepatitis C
11. Groundbreaking research to find vaccine for hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... If you don’t mind a ... your skin, you may want to consider a treatment that some have called the ... Dermatology P.C. , Microneedling, also known as skin needling, is a procedure using ...
(Date:5/5/2016)... Harbor City, NJ (PRWEB) , ... May 05, ... ... MAP Recovery Network Behavioral Health Population Management Platform, announced today that Enlightened Solutions ... will have the ability to optimize the care continuum for their patients being ...
(Date:5/5/2016)... ... May 05, 2016 , ... Nepenthe Laboratory Services (NLS), a premier drug ... to raise non-perishable food item donations for Food for Lane County, and to help ... , “The goal of the assembly was to create an exciting atmosphere for the ...
(Date:5/5/2016)... ... 05, 2016 , ... In an effort to increase public ... health promotion and research organization, declared May as “National Sunshine Month.” , ... in cultural behavior over the past several decades, Americans spend more time indoors ...
(Date:5/4/2016)... Viejo, CA (PRWEB) , ... May 04, 2016 , ... ... Final Cut Pro X . With ProList, editors can easily create lists ... stack presets to create additional bullet points. ProList is the perfect complement to ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... , May 5, 2016 /PRNewswire/ ... announced the addition of the  "Europe ... - 2016"  report to their offering.  ... ) , ,The latest research ... Highlights - 2016, provides comprehensive insights ...
(Date:5/4/2016)... Holdings (NYSE: CODI ) ("CODI," "we," "our" ... businesses, announced today its consolidated operating results for the ... Quarter 2016 Highlights , Generated Cash Flow Available ... $13.6 million for the first quarter of 2016; ... first quarter of 2016; , Paid a first ...
(Date:5/4/2016)... , May 4, 2016 BiondVax ... CEO, Dr. Ron Babecoff , will be attending the ... City . On Thursday, May 5, Dr. ... conference presented by Joseph Gunner & Co, taking ... BiondVax presentation that Dr. Babecoff will be using is downloadable ...
Breaking Medicine Technology: